Regulon Holdiing AG, is a new entity of Regulon Inc., a cancer therapy company established in Mountain View, California. Regulon Inc. has developed liposome encapsulated cancer drugs, which have demonstrated tumor targeting and substantially reduced toxicity compared to conventional cancer drugs. The main product Lipoplatin, liposome-encapsulated cisplatin has shown good safety, significantly reduced toxicity and strong tumor regression in preclinical animal models and in clinical trials in patients with various cancers. Based on phase III trials, Regulon anticipates to receive approval for Lipoplatin in the near future.
Regulon Holding AG will focus its activities on vaccine development applying our experience of self-amplifying RNA vectors based on Semliki Forest virus.
Regulon Holding AG will focus on vaccine development in three main indication areas using Semliki Forest virus (SFV) vectors:
1. Infectious diseases, primarily targeting SARS-CoV-2 and vaccines against COVID-19. Our apporach is to introduce innovative SARS-CoV-2 sequences into the SFV vector, generate self-amplifying recombinant SFV particles and liposome-encapsulated RNA particles for immunization studies in animal models to achieve protection against challenges with SARS-CoV-2.
2. Cancer immunotherapy, based on the same technology as described for infectious diseases to demonstrate protection challenges with tumor cells.
3. Tropical diseases, to develop vaccine candidates against diseases like malaria, lesihmanosis, etc using the same technology as above.
Regulon Holding AG
Route de la Corniche 5